Opaganib

Opaganib
Legal status
Legal status	Investigational new drug;
Identifiers
	IUPAC name 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)adamantane-1-carboxamide;
CAS Number	915385-81-8;
PubChem CID	15604015;
DrugBank	12764;
ChemSpider	13079494;
UNII	DRG21OQ517;
ChEBI	CHEBI:124965;
ChEMBL	ChEMBL2158685;
CompTox Dashboard (EPA)	DTXSID801318727 ;
Chemical and physical data
Formula	C23H25ClN2O
Molar mass	380.92 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C2CC3(CC1CC(C2)(C3)C(=O)NCC4=CC=NC=C4)C5=CC=C(C=C5)Cl;
	InChI InChI=1S/C23H25ClN2O/c24-20-3-1-19(2-4-20)22-10-17-9-18(11-22)13-23(12-17,15-22)21(27)26-14-16-5-7-25-8-6-16/h1-8,17-18H,9-15H2,(H,26,27); Key:CAOTVXGYTWCKQE-UHFFFAOYSA-N;

Opaganib (ABC294640) is a drug which acts as an inhibitor of the enzyme sphingosine kinase 2, dihydroceramide desaturase (DES1), and glucosylceramide synthase (GCS).^[1] It is under development as a potential treatment agent for several different kinds of cancer.^[2]^[3] Opaganib has also demonstrated antiviral activity against SARS-CoV-2 and has shown a reduction in mortality among patients with moderately severe COVID-19 in a multinational Phase 2/3 clinical trial and also appeared to exhibiting anti-inflammatory effects by reducing levels of IL-6 and TNF-alpha.^[1]^[4]